The disproportionate prevalence of migraine among women in their reproductive years underscores the clinical significance of migraine during pregnancy. This paper discusses how migraine evolves during pregnancy, secondary headache disorders presenting in pregnancy and puerperium, and acute and preventive options for migraine management during pregnancy and lactation. Migraine is influenced by rising estrogen levels during pregnancy and their sharp decline in puerperium. Migraine, and migraine aura, can present for the first time during pregnancy and puerperium. There is also a higher risk for the development of preeclampsia and cerebrovascular headache during these periods. New or refractory headache, hypertension, and abnormal neurological signs are important "red flags" to consider. This paper reviews the diagnostic utility of neuroimaging studies and the risks of each during pregnancy. Untreated migraine can itself lead to preterm delivery, preeclampsia, and low birth weight infants. Behavioral interventions and lifestyle modifications are the cornerstone for migraine treatment during pregnancy. In addition, one should consider the risks and efficacy of each treatment during pregnancy on an individual basis. The protective nature of breastfeeding for migraine is debated, but there is no evidence to suggest breastfeeding worsens migraine. Acute and preventive migraine treatment options are available for nursing mothers. Neuromodulation and neurostimulation devices are additional options for treatment during pregnancy and lactation, while the safety of using calcitonin gene-related peptide receptor antagonists during these times remains to be determined.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/bs.pbr.2020.07.011 | DOI Listing |
PLoS One
January 2025
Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China.
Background: Vitamin D is thought to play a role in the development of migraine, but the nature of the relationship is still not fully understood. Although some studies have shown an association between vitamin D deficiency and migraine, other studies have had inconsistent or inconclusive results. Therefore, further research is needed to better understand the relationship between vitamin D and migraine headaches.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, Sydney, NSW, Australia.
Background: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a rare, hereditary cerebrovascular disease which causes stroke, complex migraine, and cognitive impairment. Given its monogenic nature, CADASIL is considered a 'pure' model of small vessel disease and vascular dementia. CADASIL is caused by NOTCH3 pathogenic variants with a broad resulting phenotypic spectrum.
View Article and Find Full Text PDFCurr Opin Clin Nutr Metab Care
December 2024
Brain, Performance and Nutrition Research Centre, Faculty of Health and Life Sciences, Northumbria University, UK.
Purpose Of Review: Sleep disturbance and low dietary intake of omega-3 fatty acids are common in modern society. Previous research shows that omega-3 fatty acids play an integral role in the regulation of sleep processes, but efficacy data in adults have been equivocal to date. This review examines recent studies highlighting the effects of omega-3 fatty acids on sleep quality and circadian processes.
View Article and Find Full Text PDFNutr Rev
January 2025
Dieta, Salud Planetaria y Rendimiento, Facultad de Ciencias de la Salud, Universidad Francisco de Vitoria, 28223 Pozuelo de Alarcón, Madrid, Spain.
Context: Migraine is a disabling neurological disorder. Diet may be a factor to consider because measures of diet quality have been linked to both frequency and severity of attacks.
Objectives: To investigate the effects of dietary interventions on the clinical symptoms of migraine, quality of life, and body composition of patients with migraine.
Clin Trials
January 2025
Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Background: In randomized clinical trials, multiple-testing procedures, composite endpoints, and prioritized outcome approaches are increasingly used to analyze multiple binary outcomes. Previous studies have shown that correlations between outcomes influence their sample size requirements. Although sample size is an important factor affecting the choice of statistical methods, the power and required sample sizes of methods for analyzing multiple binary outcomes have yet to be compared under the influence of outcome correlations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!